• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高通量筛选鉴定阿克拉霉素为 EGFR 突变型非小细胞肺癌的放射增敏剂。

High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer.

机构信息

Department of Therapeutic Radiology, Yale University, New Haven, CT.

出版信息

Transl Oncol. 2013 Jun 1;6(3):382-91. doi: 10.1593/tlo.13232. Print 2013 Jun.

DOI:10.1593/tlo.13232
PMID:23730419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3660808/
Abstract

The endoplasmic reticulum (ER) provides a specialized environment for the folding and modification of trans-membrane proteins, including receptor tyrosine kinases (RTKs), which are vital for the growth and survival of malignancies. To identify compounds which disrupt the function of the ER and thus could potentially impair cancer cell survival signaling, we adapted a set of glycosylation-sensitive luciferase reporters for the development and optimization of a cell-based high-throughput screen (HTS). Secondary screens for false-positive luciferase activation and tertiary lectin-based and biochemical analyses were also devised for compound triage. Through a pilot screen of 2802 compounds from the National Cancer Institute (NCI) chemical libraries, we identified aclacinomycin (Acm) as a compound that preferentially affects ER function. We report that Acm reduces plasma membrane expression of glycoproteins including epidermal growth factor receptor (EGFR) and Met but does not inhibit N-linked glycosylation or generalized protein translation. Fluorescence microscopy co-localization experiments were also performed and demonstrated Acm accumulation in the ER in further support of the overall HTS design. The consequences of Acm treatment on cell survival were analyzed through clonogenic survival analysis. Consistent with the reduction of EGFR levels, pretreatment with Acm sensitizes the EGFR-mutant non-small cell lung cancer (NSCLC) cell lines HCC827 and HCC2935 to ionizing radiation and did not affect the sensitivity of the RTK-independent and KRAS-mutant A549 NSCLC cell line. Thus, Acm and similar compounds targeting the ER may represent a novel approach for radiosensitizing tumor cells dependent on RTK function.

摘要

内质网(ER)为跨膜蛋白的折叠和修饰提供了一个特殊的环境,包括受体酪氨酸激酶(RTKs),它们对恶性肿瘤的生长和存活至关重要。为了鉴定破坏 ER 功能的化合物,从而可能损害癌细胞存活信号,我们适应了一组糖基化敏感的荧光素酶报告基因,用于开发和优化基于细胞的高通量筛选(HTS)。还设计了用于化合物分类的二次筛选,以排除假阳性荧光素酶激活,以及基于三级凝集素的和生化分析。通过对来自国家癌症研究所(NCI)化学文库的 2802 种化合物进行初步筛选,我们发现阿克拉霉素(Acm)是一种优先影响 ER 功能的化合物。我们报告说,Acm 降低了包括表皮生长因子受体(EGFR)和 Met 在内的糖蛋白的质膜表达,但不抑制 N 连接糖基化或普遍的蛋白质翻译。荧光显微镜共定位实验也进行了,并证明 Acm 在 ER 中的积累进一步支持了整个 HTS 设计。通过集落形成生存分析分析了 Acm 处理对细胞存活的影响。与 EGFR 水平降低一致,Acm 预处理使 EGFR 突变型非小细胞肺癌(NSCLC)细胞系 HCC827 和 HCC2935 对电离辐射敏感,并且不影响 RTK 非依赖性和 KRAS 突变型 A549 NSCLC 细胞系的敏感性。因此,针对 ER 的 Acm 类似物可能代表一种针对依赖 RTK 功能的肿瘤细胞的新型放射增敏方法。

相似文献

1
High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer.高通量筛选鉴定阿克拉霉素为 EGFR 突变型非小细胞肺癌的放射增敏剂。
Transl Oncol. 2013 Jun 1;6(3):382-91. doi: 10.1593/tlo.13232. Print 2013 Jun.
2
Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy.分子成像的 N-连接糖基化表明糖生物合成是癌症治疗的一个新靶点。
Clin Cancer Res. 2010 Jun 15;16(12):3205-14. doi: 10.1158/1078-0432.CCR-09-3331. Epub 2010 Apr 22.
3
Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.雌激素受体 β1 的激活加速了非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性。
Oncol Rep. 2018 Mar;39(3):1313-1321. doi: 10.3892/or.2018.6186. Epub 2018 Jan 4.
4
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.敲低表皮生长因子受体基因以研究其治疗非小细胞肺癌的治疗潜力。
Clin Lung Cancer. 2012 Nov;13(6):488-93. doi: 10.1016/j.cllc.2012.02.003. Epub 2012 Apr 12.
5
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.泛组蛋白去乙酰化酶(HDAC)抑制剂帕比司他可作为厄洛替尼在表皮生长因子受体(EGFR)突变型和野生型非小细胞肺癌细胞中发挥活性的增敏剂。
BMC Cancer. 2015 Dec 16;15:947. doi: 10.1186/s12885-015-1967-5.
6
β-Apopicropodophyllin functions as a radiosensitizer targeting ER stress in non-small cell lung cancer.β-蜕皮甾酮通过靶向作用内质网应激增强非小细胞肺癌放射敏感性
Biomed Pharmacother. 2019 May;113:108769. doi: 10.1016/j.biopha.2019.108769. Epub 2019 Mar 11.
7
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼与芳香化酶抑制剂阿那曲唑联合应用于非小细胞肺癌细胞系的协同作用。
Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15.
8
miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.miR-19b 通过靶向非小细胞肺癌中的 PP2A 和 BIM 增强 EGFR 信号通路促进增殖和抗凋亡。
Mol Cancer. 2018 Feb 19;17(1):44. doi: 10.1186/s12943-018-0781-5.
9
[Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].吉非替尼抑制对HCC827和H358细胞系非小细胞肺癌放射敏感性的影响及机制
Zhongguo Fei Ai Za Zhi. 2012 Jun;15(6):324-31. doi: 10.3779/j.issn.1009-3419.2012.06.02.
10
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.缺氧诱导具有突变和野生型表皮生长因子受体的非小细胞肺癌对吉非替尼产生耐药性。
Cancer Sci. 2012 Nov;103(11):1946-54. doi: 10.1111/j.1349-7006.2012.02408.x. Epub 2012 Sep 14.

引用本文的文献

1
A light-resuming strategy as a screening method for selecting Sec61 inhibitors down-modulating PD-L1 expression.一种作为筛选下调PD-L1表达的Sec61抑制剂的筛选方法的光恢复策略。
Nat Commun. 2025 Aug 6;16(1):7243. doi: 10.1038/s41467-025-62439-w.
2
STT3A-mediated mega protein complex assembly during dengue and Zika virus infection.登革热和寨卡病毒感染期间STT3A介导的巨型蛋白复合体组装
iScience. 2025 Apr 28;28(6):112535. doi: 10.1016/j.isci.2025.112535. eCollection 2025 Jun 20.
3
Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.阿克拉霉素:作用机制、毒性、药代动力学和临床地位的现代认识。
Cancer Chemother Pharmacol. 2024 Aug;94(2):123-139. doi: 10.1007/s00280-024-04693-1. Epub 2024 Jul 4.
4
Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity.鉴定吲哚菁绿为 STT3B 抑制剂,对抗蕈类α-鹅膏蕈碱细胞毒性。
Nat Commun. 2023 May 16;14(1):2241. doi: 10.1038/s41467-023-37714-3.
5
Signal recognition particle receptor-β (SR-β) coordinates cotranslational N-glycosylation.信号识别颗粒受体-β(SR-β)协调共翻译 N-糖基化。
Sci Adv. 2023 Mar 17;9(11):eade8079. doi: 10.1126/sciadv.ade8079. Epub 2023 Mar 15.
6
Single-Cell Transcriptome Comparison of Bladder Cancer Reveals Its Ecosystem.膀胱癌单细胞转录组比较揭示其生态系统
Front Oncol. 2022 Feb 21;12:818147. doi: 10.3389/fonc.2022.818147. eCollection 2022.
7
A bioactive mammalian disaccharide associated with autoimmunity activates STING-TBK1-dependent immune response.一种与自身免疫相关的生物活性哺乳动物二糖激活 STING-TBK1 依赖性免疫反应。
Nat Commun. 2019 May 30;10(1):2377. doi: 10.1038/s41467-019-10319-5.
8
Immune Diseases Associated with TREX1 and STING Dysfunction.与TREX1和STING功能障碍相关的免疫疾病
J Interferon Cytokine Res. 2017 May;37(5):198-206. doi: 10.1089/jir.2016.0086.
9
Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.寡糖基转移酶抑制可诱导受体酪氨酸激酶驱动的肿瘤细胞衰老。
Nat Chem Biol. 2016 Dec;12(12):1023-1030. doi: 10.1038/nchembio.2194. Epub 2016 Oct 3.
10
Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation.胞质核酸酶TREX1独立于核酸酶活性调节寡糖基转移酶活性以抑制免疫激活。
Immunity. 2015 Sep 15;43(3):463-74. doi: 10.1016/j.immuni.2015.07.022. Epub 2015 Aug 25.

本文引用的文献

1
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.MEHD7945A 双重靶向 EGFR 和 HER3 可克服对 EGFR 抑制剂和辐射的获得性耐药。
Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20.
2
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.野生型 EGFR 在癌细胞和肿瘤中通过与 HSP90 的直接相互作用而稳定。
Neoplasia. 2012 Aug;14(8):670-7. doi: 10.1593/neo.12986.
3
Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screen.在高通量筛选中鉴定出的蛋白质甲基转移酶SET7/9的小分子抑制剂。
J Biomol Screen. 2012 Sep;17(8):1102-9. doi: 10.1177/1087057112452137. Epub 2012 Jul 5.
4
Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops.组成性二聚化的致癌性 EGF 受体通过自分泌环的过度激活。
Oncogene. 2013 May 9;32(19):2403-11. doi: 10.1038/onc.2012.267. Epub 2012 Jul 2.
5
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.CAG(阿糖胞苷、阿克拉霉素、G-CSF)方案治疗 1029 例急性髓系白血病和骨髓增生异常综合征患者的荟萃分析。
J Hematol Oncol. 2011 Nov 14;4:46. doi: 10.1186/1756-8722-4-46.
6
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.黏蛋白糖基化酶 GALNT2 通过修饰表皮生长因子受体调节肝癌的恶性特征。
Cancer Res. 2011 Dec 1;71(23):7270-9. doi: 10.1158/0008-5472.CAN-11-1161. Epub 2011 Oct 11.
7
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗(OPTIMAL、CTONG-0802):一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
8
Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.表皮生长因子受体的唾液酸化和岩藻糖化抑制肺癌细胞中的二聚化和激活。
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11332-7. doi: 10.1073/pnas.1107385108. Epub 2011 Jun 27.
9
Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.成纤维细胞生长因子受体 3(FGFR3)是一种强烈的热休克蛋白 90(Hsp90)客户:对治疗干预的影响。
J Biol Chem. 2011 Jun 3;286(22):19597-604. doi: 10.1074/jbc.M110.206151. Epub 2011 Apr 12.
10
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.通过一种新型高通量筛选方法鉴定和验证 Notch 通路激活化合物。
Cancer. 2011 Apr 1;117(7):1386-98. doi: 10.1002/cncr.25652. Epub 2010 Nov 8.